Method and preparation for pathogenetic therapy of diseases due to tissue-specific regulation of hepatic mitochondrial processes (variants)

FIELD: medicine.

SUBSTANCE: it has been suggested the method for introducing a preparation in efficient dosage being either a substance or preparation prepared according to homeopathic technique or biologically active additive that contains a substance isolated out of hepatic cells being slightly hydrophobic, water-soluble, negatively charged at alkaline pH, at molecular weight ranged 500-15000 Da that enables to decrease tissue-specifically the ratio of phosphorylated adenosine diphosphate against the quantity of atomic oxygen spent by highly energized mitochondria in the course of oxidizing phosphorylation. The suggested method and preparation enable to treat efficiently astheno-depressive state and, also, increases the efficiency of complex therapy of pulmonary and intestinal diseases.

EFFECT: higher efficiency of therapy.

16 cl, 21 ex

 

The technical field

The invention relates to medicine, namely to methods and means of pathogenetic therapy of diseases and/or physiological systems that are functionally dependent on the liver, through therapeutic effects on the liver tissue-specific regulation in her mitochondrial processes.

Prior art

Currently, it is well known that various diseases caused by these or other sustainable violations of cellular homeostasis. Last, mainly supported by the functioning of the mitochondria. Based on these representations when pathogenetic therapy of various diseases apply metabolites of the tricarboxylic acid cycle (succinate) [Therapeutic use succinic acid. Edited Menandrou. Pushchino, USSR Academy of Sciences, 1976, s], as well as substances involved in the electron transfer in the respiratory chain of mitochondria, such as coenzyme Q10 [Iaacocca, Ophrys. A comparative study of the bioavailability of coenzyme Q10 in different dosage forms. Bulletin of PFUR, series Medicine, 2000, No. 2, p.71-73] and cytochrome C [Mascolini, Evelution. Indicators of oxidative metabolism and antioxidant defense in patients with chronic obstructive bronchitis complicated with chronic pulmonary heart, and their changes during treatment. Pulmonologist who I am, 2002, vol.12, No. 4, p.45-49].

It is well known that endogenous regulators are more effective means of treatment of diseases compared to synthetic. Of particular interest as a means of treating diseases are endogenous regulators with tissue specificity of action on mitochondrial processes in producing these regulators cells.

Known regulators from various animal tissues, which include Chalons [Bullough W.S., 1973. The Chalones: A Review. Natl. Cancer Inst. Monogr. V.38, p.5-15], contactin [Yamskov VP, Modyanova E.A., M. Reznikov, Malenkov A.G. Highly tkanevospetsificheskie adhesion factors of liver and lung of rats. Mol. biology, 1977, t, Vol.5, s-1154], cytomedines [Morozov V.G., Khavinson V.H. New class of biological regulators multicellular systems - cytomedines. The success of contemp. Biol., t, 1983, issue 3 (6), s-352] and catamini [Morozov V.G., Ryzhak GA, Malinin V.V., kN. "Catamini - regulation of cellular metabolism", St. Petersburg, 2001, pp. 102]. They can be considered as equivalents, as have a number of common properties with the regulator contained in the proposed tool, namely the tissue specificity of action on the processes taking place in homologous tissue, in the absence of the species specificity of the action.

The chemical structures of these regulators are poorly understood. Therefore, to use Henichesk the th structure of these substances as a criterion for their identification is not possible. On the other hand, studies of the mechanism of action of these regulators have shown that they are qualitatively different from each other at the place of application of its direct impact on the subcellular level. For example, the inhibitory action of some of Chalons on the proliferative activity of the tissue due to their interaction with the cell surface [Aardal N.., O.D. Laerum, Paukowits W.R., H.R. Maurer Inhibition of agar colony formation by partially purified Granulocyte extracts (Chalone). Virchows Arch. Abt. B. Cell Path., 1977, Bd 24, §27-39]. It is widely accepted that the effect of epidermal G2-kalona in all tissues mediated by cyclic amp. A similar mechanism can be realized only if Ceylon interacts with the surface of the plasma membrane [Neustroev, G.V. Influence of erythrocyte kalona on postsinteticescuu period of mitotic cell cycle erythroblastosis number of bone marrow of mice. Arch. Anat., 1980, No. 7, pp.69-73]. Regulation of cell proliferation by ContactName due to increases in their cell adhesion [Malenkov A.G., Modyanova E.A., Yamskov VP tissue-specific adhesion factors - G1-Chalons. Biophysics, 1977, t, N1, s-157]. Thus, it is established that contactin as Chalons, a direct impact on the cell surface.

There is evidence that tissue-specific regulators can carry out its functions, affecting eposredstvenno on the cell nucleus. Thus, G1-Ceylon from breast cancer has the ability to inhibit the synthesis of DNA in the cell nucleus, organizing it block between pool timeinterest and DNA [Gonzalez R., Verly W.G. Purification of an inhibitor of DNA synthesis in mammary cells. Europ. J. Cancer., 1978, vol.14, N 6, p.689-697]. The action of citomedines as regulators of the activity of the genome of the cells also explain their direct interaction with the DNA of the cell nucleus [Morozov V.G., Khavinson V.H. New class of biological regulators multicellular systems - cytomedines. The success of contemp. Biol., t, 1983, issue 3 (6), s-352].

From the foregoing it can be concluded that significant and reliable criterion for differentiation of tissue-specific regulators of cellular processes at the present time it is the place of their direct impact on the subcellular level to different cellular organelles, such as, for example, in the above cases on the surface of the plasma membrane (Chalons, contactin) or on the cell nucleus (cytomegaly).

The closest is a method of treatment of diseases of the tool, dubbed "catamini" [Morozov V.G., Ryzhak GA, Malinin V.V., kN. "Catamini - regulation of cellular metabolism", St. Petersburg, 2001, pp. 102]. Catamini represent a high molecular weight interpolymer complexes containing tissue-specific proteins, RNA and DNA. Such nucleoprotein complexes are components of the nuclear chromatin, i.e. localized in the cell nucleus (see p.7-8 [Morozov V.G., Ryzhak GA, Malinin V.V., kN. "Catamini - regulation of cellular metabolism", St. Petersburg, 2001, pp. 102]). In Russia the patented method of obtaining titomirov [Morozov V.G., Khavinson V.H. Way to obtain protein, nutritional supplements. Pat. 2075944 RF from 27.03.1997, BI No. 9]. Catamini in the form of a dietary Supplement used for the treatment and prevention of diseases homologous applicable titaninum tissues of the human body and, in particular, for the treatment of diseases of the liver and kidney, the treatment of which is described in [Morozov V.G., Ryzhak GA, Malinin V.V. "Catamini - regulation of cellular metabolism", St. Petersburg, 2001, pp. 102]. It should be noted that we cannot exclude the possibility of indirect effects of titomirov mitochondria of homologous tissue. However, data indicating such an influence, not in the scientific literature. The possibility of any impact titlename mitochondria of homologous tissue in it not even discussed.

In the last half of the 20th century the regulation of energy products and ion transport in mitochondria from animal tissues have been subjected to intensive study. When this object was to study the regulatory mechanisms that are common to all tissues of a living organism [Bullough W.S., 1973. The Chalones: A Review. Natl. Cancer Inst. Monogr. v.38, p.5-15]. Tissue-specific regulatory mechanism energos is independent processes in the mitochondria of animal tissues was detected by one of the authors [elbakidze G.M., Livanov L.M. ON the tissue-specific disconnector oxidative phosphorylation mitochondria. Bull. Exp. Biol. Med., 1977, No. 7, p.32-35; elbakidze G.M. tissue-specific uncouplers of oxidative phosphorylation mitochondria from the heart, kidneys, thymus and liver of the rat. Bull. The experimental. Biol. Med., 1979, t, No. 2, s-151] and nobody before him has not been studied.

In scientific literature there are also no data on the use of (or assumptions about the application) tissue-specific operating endogenous regulators isolated from the liver for the treatment of diseases of other organs and physiological systems.

Disclosure of inventions

The technical result of the invention is to increase the efficiency of pathogenetic therapy of various diseases of individual organs or physiological systems of the body.

The technical result is achieved by the fact that the proposed remedy and a way of pathogenetic therapy of diseases and/or physiological systems that are functionally dependent on the liver, through tissue-specific regulation of mitochondrial processes in liver cells, including the introduction of effective dose in the body of the tool or allopathic, or preparation, prepared according to homeopathic technology, or dietary supplements that contain ve is estvo, isolated from the liver, or from a culture of liver cells, or obtained by the methods of biotechnology, which slabovidimym, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 Da to 15000 Yes, while the substance in question is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen (ADP/O). In particular, the oxidation of mitochondrial succinate ADP/O is reduced to a value less than 1.8, up to the complete uncoupling of oxidative phosphorylation.

The use of the proposed substance - tissue-specific regulator of mitochondrial processes of the liver as a means for pathogenetic treatment of disease is obvious, and not the original and first proposed by the authors in this invention.

Further, throughout the text of the proposed variants of the method of pathogenetic therapy will be referred to as "treatment"options proposed tools will be referred to as "Tool". Further, throughout the text of the proposed variants of the method of obtaining the Funds will be called "the Method of obtaining the Means."

To refer to biologically active additives will be at enano common abbreviation "BAD". The matter will be referred to as "Regulator"because it is found that it regulates mitochondrial processes. Method of assessment deenergized regulatory actions on mitochondria the ratio of ADP/O will hereinafter be called "the ADP/O test". It is well known that the decrease of the ratio of ADP/O in mitochondria is an indicator of deenergisation (damage) mitochondria [Skulachev V.P. Transformation of energy in biomembranes. M.: Nauka, 1972, p.5, pp.31-32, p.45-53].

The difference of the present invention is first proposed method of use of Funds on the basis of the Regulator from the liver for the treatment of other organs and physiological systems of human and animal, are functionally dependent on the liver (a Method of treatment of this Tool). Also for the first time shows the results of therapeutic action of the product on the basis of the Regulator from the liver cells of an animal person. Particular Means and method of treatment is reflected in the combination of features of the claims.

From the above publications [elbakidze G.M., Livanov L. the Study of species specificity of action of tissue-specific disconnector oxidative phosphorylation mitochondria from rat liver. WPI. An SSSR, Ser. Biol., 1981, No. 1, s-153; elbakidze G.M., Fogel A.G., Majewski H., bohua BT, Chelidze M.A., elbakidze IM, Gordeziani MS Study tissue-specific CA2+for what esimai regulation of mitochondrial processes thermostable kautonen from rat liver. Reports of the Academy of Sciences, 1992, CH, No. 1, s-219; elbakidze G.M., Chelidze M.A., elbakidze IM tissue-specific regulation of the transport of calcium ions thermostable kautonen from rat liver. Reports of the USSR Academy of Sciences, 1990, t, No. 2, s-478] data selected substances Regulator does not imply the possibility of its application as a therapeutic agent. At present it is not known to have tissue-specific mitochondrial damage in the liver, accompanied by deenergization mitochondria, leading to therapeutic effects in the organs and physiological systems that are functionally dependent on the liver. These therapeutic effects, we found, for the first time set out here are the technical result of the invention.

The difference of the Means is the possibility of using tissue-specific, but vidospetsifichnymi intracellular mechanisms regulating the efficiency of energy products in liver mitochondria for pathogenetic therapy of organs or physiological systems that are functionally dependent on the liver. When this is the condition that in each case applied tissue-specific Regulator isolated from liver cells or from the culture of liver cells, or obtained by the methods of biotechnology for the treatment of a human or vertebrate animal of any species of incompatibility the property.

The difference Means is that the Regulator from the liver exerts tissue-specific effects on the efficiency of energy-dependent processes in the mitochondria, through the direct interaction of the Controller with the mitochondria in the cells of the same tissue.

The difference Means is that the Regulator of the liver has vidospecificskie impact on the efficiency of energy-dependent processes in the mitochondria, through the direct interaction of the Controller with the mitochondria in the cells of the same tissue.

The distinctive characteristics of the Regulator are molecular weight in the range from 500 to 15000 Yes, solubility, weak negative charge at alkaline pH and weak hydrophobic properties. Carried out researches have allowed to establish that the Regulator found in rat liver and in the liver of various vertebrates, has on vysokotochnye mitochondria of homologous tissue of the same tissue-specific effect, namely, it is able to lower the efficiency of oxidative phosphorylation in these mitochondria, resulting in lowering of the relationship ADP/O ratio the efficiency of this process, measured as the ratio of phosphorylated by mitochondria oxidizing succinate, ADP expended is in the process of oxidative phosphorylation quantity of atomic oxygen to a value of less than 1.8, until the complete uncoupling of oxidative phosphorylation.

The mechanism deenergized expire isolated from liver mitochondria of homologous tissue, which consists in the induction of the inner membranes of these mitochondrial permeability for cations [elbakidze G.M., Fogel A.G., Majewski H., bohua BT, Chelidze M.A., elbakidze IM, Gordeziani MS Study tissue-specific CA2+-dependent regulation of mitochondrial processes thermostable kautonen from rat liver. Reports of the Academy of Sciences, 1992, CH, No. 1, s-219].

The technical result is also achieved by the fact that the method of obtaining Funds, including the gradual release of the active substances (Regulator) - active component funds (cash) using standard methods biochemistry, and after each step was controlled by the activity of the substance (Regulator) using the ADF-test, identifying the substance (the Regulator), secreted from the liver of an animal or cell culture or derived through biotechnology, by testing first, he deenergizes action on the source vysokomineralizovannye mitochondria isolated from the liver of the animal; secondly, in the absence of its deenergized actions on the source vysokomineralizovannye mitochondria any other tissue of incompatibility is STI, i.e. tissue specificity of its deenergized actions; thirdly, the lack of species specificity of its deenergized steps on the source vysokomineralizovannye mitochondria isolated from the liver of any animal of another species.

Thus, at each stage of the allocation process Controller we first proposed to establish that the active principle really Means is the Controller.

To uniquely identify the Controller applies a test system that allows three separate experiments together the similarities and differences between their results to identify marker Governor properties, namely its ability tissue-specific and lack of species specificity to energysouth vysokomineralizovannye mitochondria of homologous tissue.

The degree of energizante mitochondria in all three experiments evaluated the standard method the ratio of ADP/O, reflecting the efficiency of oxidative phosphorylation (ADP/O-test). The maximum value of this quantity at vysokomineralizovannyh mitochondria from any tissue of an animal of any species, oxidizing succinate in standard experimental conditions for suspension of mitochondria, may not exceed a value of 2.0. In the proposed test system was used mitochondria with respect to the ADP/O in the interval of values of 2.0 and 1.8. Reliable effect deenergization mentioned mitochondria tested fraction from liver extracts or subcellular fractions, or fractions of different degrees of purification, namely, partially purified or purified) believed the decrease in ADP/O to the value of this ratio less than 1.8 in the presence of the mentioned fractions (ADF-test). However, it is possible and complete separation of oxidative phosphorylation of mitochondria tested faction.

When testing the Controller in the ADP/O-test succinate can be replaced by any other substrate oxidation.

List of experiments conducted to identify the Controller in his marker properties given in direct sequence.

Experiment No. 1. Check deenergized steps of the test biological material from the liver to the drug source vysokomineralizovannyh mitochondria isolated from the liver of an animal of the same species.

Is the measurement of the ADP/O in standard conditions, when oxidation in liver mitochondria succinate in an incubation medium containing no other factions. Then the ADP/O-test is repeated in the presence of the test biological material isolated from an animal of the same species, and that the mitochondria from the liver.

A positive result at this stage of testing is that the test is imago biological material ability to energysouth vysokomineralizovannye mitochondria, as evidenced by the lowering of the relationship ADP/O.

Experiment No. 2. Test tissue specificity deenergized steps of the test biological material from the liver to vysokomineralizovannyh mitochondria of heterologous tissue of an animal of the same species.

Experiment No. 2 is held in the case of a positive result in experiment No. 1. Its purpose is to study deenergized steps of the test biological material from the liver under the scheme of Experiment No. 1, but on mitochondria isolated from any other tissue of an animal of the same species. A positive result at this stage of testing is the inability of the tested biological material from the liver to energysouth mitochondria of heterologous tissue of an animal of the same species as the source of the test biological material, as evidenced by the lack of effect of lowering relationships ADP/O.

Experiment No. 3. Check the species specificity of action of the tested biological material from the liver to vysokomineralizovannyh mitochondria isolated from the liver of an animal of another species.

Experiment No. 3 is held in the case of positive results in experiments 1 and 2. Its purpose is to study deenergized steps of the test biological mother of the La from the liver under the scheme of Experiment No. 1, but on mitochondria isolated from the liver of any animal of another species. A positive result at this stage of the test lies in the ability of the test biological material to energysouth source vysokomineralizovannye mitochondria same fabric accessories, but selected from the same tissue of an animal of another species, as evidenced by the lowering of the relationship ADP/O.

The regulator is uniquely identified in this test system in obtaining positive results in Experiments No. 1-3 in their inalienable together.

The above list of experiments does not depend on the tested biological material. They may be extracts from liver cells, or subcellular fraction, or a separate partially purified fractions, or purified Regulator, and the fraction obtained from the best practices of the Regulator with the use of biotechnology techniques.

Described testing allows you to set the Regulator at each stage of the process of obtaining drugs partially purified and purified Regulator of liver.

Note that testing the activity of the Regulator during fractionation (identification of damaged mitochondria in experiments # 1 and # 3 and the lack of detection in the experiment No. 2) can be carried out not only by the ADP/About-those whom one but:

- reduction of transmembrane potential;

according to the degree of vosstanovlenie matrix pool prenucleation;

- reduction of calcium capacity of mitochondria;

- reduction of time of deduction of mitochondrial calcium ions;

- by stimulating the activity of ATP-ASE.

This Controller will also be clearly identified, but in the above test systems in obtaining positive results in Experiments No. 1-3, an integral whole.

Based on the study of the behavior of Regulators isolated from liver of any species of vertebrate animals, preparative procedures (stages of the selection Controller) concluded about the existence of the General physico-chemical properties: the total negative charge in alkaline medium, low hydrophobicity, water solubility and the range of molecular weight from 500 to 15000 Da.

The technical result is also achieved by the fact that the proposed Tool can be made in the form of homeopathic remedies, as well as allopathic remedies (including only substances Control) or in the form of the BAD, and the Controller is obtained by extraction from liver cells of an animal or from a culture of liver cells or are being developed through biotechnology.

The technical result before thetsa fact, that:

- substance (the Regulator) is present in the composition of the extract, with a gradual release of the active substances (Regulator) is terminated at the stage of extraction;

- substance (the Regulator) is present in the composition of subcellular fractions, with a gradual release of the active substances (Regulator) is terminated at the stage of centrifugation or ultracentrifugation;

- offered partially purified substance (the Regulator), with a gradual release of the active substances (Regulator) is terminated at the stage of column chromatography low pressure;

- features a purified substance (the Regulator), with a gradual release of the active substances (Regulator) is terminated at the stage of carrying out electrophoresis.

The technical result is also achieved by the fact that the Means in the form of a substance (Regulator) is injected or oral, including sublingual, or in the form of injections. The applied doses are recommended in each specific case, taking into account the route of administration, type of illness and the severity of the patient.

The technical result is also achieved that can be applied to a wide range of homeopathic dilutions of purified substances Control. The most common is the breeding D6. However, you can use the following dilutions of the Regulator: D1 - D1000, (D1, D3, D12, D18, D24, D30, D100, D200, D1000),and 30S-S (30C, 50C, 200C and S).

Mentioned cultivation in different degree show therapeutic efficacy, which may vary in time of onset of therapeutic effect and the power of his symptoms, but not the nature of the symptoms of the pathological process.

In addition, the technical result is achieved in that the Tool is BAD, which includes the substance, optionally partially purified, effective dose (1-1000 µg) and the media. However clarified that in terms of power and effectiveness has the advantage of an effective dose of 10-100 μg.

As media SUPPLEMENTS can be used edible sugar, sucrose, sorbitol, or any other soluble non-toxic ingredients and their combinations.

In a wider range of values doses of SUPPLEMENTS also shows therapeutic efficacy, which may vary in time of onset of therapeutic effect and the power of his symptoms, but not the nature of the symptoms and objective manifestations of the pathological process.

When implementing the treatment Method supplied the technical result is achieved by the fact that the dietary Supplement is taken orally between meals mostly twice a day, and homeopathic drug is taken sublingually, with effective dose of 5-6 grains by resorption mouth to complete the RA is the creation mostly twice a day between meals.

Next, the technical result is achieved by the fact that in the proposed method pathogenetic therapy of diseases of the tissues, organs and physiological systems that are functionally dependent on the liver:

in the treatment of diseases of the Central nervous system (astheno-depressive States) take extracts or subcellular fraction, or homeopathic medicine, or dietary supplements containing the substance (the Regulator), isolated from the liver, not less than one week.

Proposed in the mentioned cases, allows to normalize the psychoemotional status of patients for a long time, for a period of not less than 6-8 months.

In the treatment of chronic obstructive pulmonary disease (COPD) take extracts or subcellular fraction, or homeopathic medicine, or dietary supplements containing the substance (the Regulator), isolated from the liver, for at least two months.

Proposed in the above-mentioned cases, when you remove the manifestations of intoxication characteristic of this disease, to improve General physical condition of the patient, and also contributes to the normalization of its weight.

In the treatment of chronic ulcerative colitis colon take extracts or subcellular fraction, or homeopathic medicine, or dietary supplements containing the substance (the Regulator), isolated from the liver, not less than one month.

Predlojeno is in these cases you can take the manifestations of intoxication, because of intestinal pathogenic flora, improve General physical condition of the patient, and reduces symptoms of ulcerative colitis.

The frequency of administration of the extract, subcellular fractions, homeopathic remedy or BAD varies depending on the type of illness, the severity of the patient from one to six times a day.

The essence of the present invention is a Method (variants) and a tool (options) pathogenetic therapy of diseases of organs and physiological systems that are functionally dependent on the liver, through tissue-specific regulation of mitochondrial processes in liver cells is proposed a new non-obvious Way (options) pathogenetic treatment of diseases of organs and physiological systems that are functionally dependent on the liver, using the new non-obvious Tools (options) for pathogenetic treatment of disease by tissue-specific regulation of mitochondrial processes in the liver, as well as a new and non-obvious method of obtaining the proposed framework.

Tool (options) in the form of a substance (Regulator) or performed on its basis (homeopathic medicines, allopathic medicines, various BAD) never previously offered and was not considered as having a therapeutic effect against diseases org is new and/or physiological systems, functionally dependent on the liver, and therefore involves an inventive step. The method proposed treatment with the use of Tools (options) also involves an inventive step. The proposed Method (variants) and a mean (range) treatment allow to increase the efficiency of pathogenetic treatment of various extrahepatic diseases of human and animal body. Tool (options) contributes to the enhancement of nonspecific resistance of the liver cells, and activation of detoxification functions of these cells. We believe that this occurs through tissue-specific optimization of functions of mitochondria to maintain energy and ion homeostasis liver cell Vehicle, based on the Controller obtained from the liver.

Analogues of the Regulator from rat liver were also detected in the liver birds, amphibia and fish [Livanov, L.M., elbakidze G.M. tissue-specific uncouplers of oxidative phosphorylation of mitochondria from liver cells of mammals, birds, amphibia and fish. WPI. An SSSR, Ser. Biol., 1980, No. 2, s.285-289]and in rabbit liver, indicating their widespread prevalence in the liver of vertebrates. This removes the question of scarcity of biological raw materials for making Tools.

Technological implementation of the invention t is the train based on known basic biochemical methods to obtain the substance (Regulator) Funds and famous homeopathic technology, or conventional pharmaceutical technology, or common cooking techniques BAD. All these technologies are widely used, and therefore, the proposal meets the criterion of "industrial applicability". The main difference in making Money is to have a Regulator that is present in the Tool.

Below the invention is explained in specific applications of products containing Regulator for pathogenetic therapy of human diseases.

Embodiments of the inventions

The present invention suggested treatment options and Remedies or which is the Regulator, or is made on the basis of the Regulator (homeopathic remedies, SUPPLEMENTS).

The regulator can be obtained not only from the liver cells of an animal of any species in the composition of the body, but the liver cells obtained by culturing organs and tissues outside the body, as well as with the application of biological technologies.

The regulator allocated to different the following examples of specific performance of the various organs of the rat and rabbit. Used various combinations of the following methods, which are the stages of the selection Controller:

1. Mechanical grinding tissue

2. Homogenization

3. Differential centrifugation

4. Extraction

5. Centrifugation

6. The ultracentrifugation

7. Dialysis

8. Thermal fractionation

9. Ultrafiltration

10. Column chromatography of low pressure

11. Column chromatography of high pressure

12. The electrophoresis.

The selection of the Regulator (i.e. the proposed substance, characterized by the set of features, data in the "claims"), which is the basis of Means of multi-component fraction is produced using modern standard preparative biochemical methods in their sequence. Each of the methods listed in their list, starting with method No. 3, allows to separate a multicomponent mixture of substances into fractions. From obtained after separation of the mixture by the method No. 3 aggregate fractions us using the test described in the test system was selected as the "active" fraction, i.e. having a specific characteristic, namely "the ability of tissue-specific lower ratio of phosphorylated to the diphosphate to the amount of atomic oxygen, spent vysokomineralizovannye mitochondria during oxidative phosphorylation". This characteristic clearly testified to the fact that within the above fraction is present in the Controller. After this "active" F. the action was subjected to separation using the method No. 4. The resulting preparative procedures faction again tested on the content of the Regulator using the test system. Cycle "preparative separation of substances testing activity Regulator" was repeated using the following methods, as long as in method No. 12 we have not received not shared with applied preparative methods the fraction containing the Controller.

From the foregoing it is seen that a high-purity Regulator is allocated from a mixture of substances, due to our development of the original test system. The uniqueness of our test system is that it not only allows to identify in the tested fractions substance deenergized mitochondria, but also to select from all of these substances Regulator with tissue specificity of action on the mitochondria of homologous tissue, in the absence of the species specificity of action, along with all the other features mentioned in the claims.

Based on the above noted explanation we claim that the developed test system allows an unambiguous we found a Controller that forms the basis of Funds, from any mixture of other substances, even if we assume that the composition of this mixture there are other substances with tissue specificity and have a Le is epnoe action when the pathogenetic treatment of different diseases. Every other substance in the composition of the test mixture will not have the whole set of features of the Regulator. From the above it also follows that the physico-chemical properties of the Controller are its additional features. Most of his sign is the tissue specificity of action on the mitochondria of homologous tissue found in the developed test system. For selection of extracts containing the Controller methods were used №№1-4.

For isolation of subcellular fractions containing the Controller methods were used No. 1-5 or No. 1-6.

For separation of partially purified preparations of Controller methods were used No. 1-10.

For isolation of purified preparations of Controller methods were used 1-12.

Below are examples of the selection Controller varying degrees of purification using the listed above are known and widely used preparative biochemical methods.

Example of getting "cell extract".

Animals (5 rats "Wistar") was scored by decapitation, the extracted liver was washed and cooled in a cold saline solution. Then cooled and washed from the blood, the liver was crushed by punching through small holes probablilites. The resulting slurry of the pieces of fabric suspended in physiological p is the target and perform the extraction for 24 hours Then the pieces of fabric besieged by centrifugation.

The obtained extract (supernatant after centrifugation) were tested on the content of the Regulator in the three experiments as follows.

Experiment No. 1. Check deenergizing action of the tested fraction of an extract of rat liver in drug source vysokomineralizovannyh mitochondria isolated from rat liver.

Made to measure ADP/O in a suspension of mitochondria isolated from rat liver, in standard conditions, the oxidation of succinate in an incubation medium containing no other factions. The ratio of ADP/O in control is equal to 1.9. Then the measurement is repeated in the same incubation medium in the presence of the tested fraction of an extract of rat liver. It is found that the ratio of ADP/O is reduced to 0.4. Therefore, we obtained an extract of rat liver (tested fraction) discovered the ability to energysouth vysokomineralizovannye mitochondria.

Achieved significant effect deenergization mentioned mitochondria in the ADP/O-test according to the above description.

Experiment No. 2. Test tissue specificity deenergizing action of the tested fraction of an extract of rat liver on the source vysokomineralizovannyh mitochondria from rat kidney.

Studied for this purpose deenergize action of the tested fraction of the extract pecan the rats according to the scheme of Experiment No. 1, but on mitochondria isolated from the rat renal, i.e. other tissues of the animal of the same species.

Made to measure ADP/O in a suspension of mitochondria isolated from the rat renal, under standard conditions, the oxidation of succinate in an incubation medium containing no other factions. The ratio of ADP/O in control is equal to 1.85. Then the measurement is repeated in the same incubation medium in the presence of the tested fraction of an extract of rat liver. It is found that the ratio of ADP/O is not changed.

Therefore, we obtained an extract of rat liver (tested fraction) not found ability to energysouth vysokomineralizovannye mitochondria isolated from heterologous tissue of an animal of the same species, as evidenced by the lack of effect of lowering relationships ADP/O.

Experiment No. 3. Check the species specificity of action of the tested fraction of an extract of rat liver on vysokomineralizovannye mitochondria isolated from the liver of the rabbit.

For this experiment according to the scheme of Experiment No. 1, but using mitochondria isolated from rabbit liver, i.e. homologous tissues of an animal of another species.

Made to measure ADP/O in a suspension of mitochondria isolated from rabbit liver, under standard conditions, the oxidation of succinate in an incubation medium containing no other f the shares. The ratio of ADP/O control is 1,95. Then the measurement is repeated in the same incubation medium in the presence of the tested fraction of an extract of rat liver. It is found that the ratio of ADP/O is 0.3.

Therefore, we obtained an extract of rat liver (tested fraction) discovered the ability to energysouth source vysokomineralizovannye mitochondria same fabric accessories, but isolated from other animal species, as evidenced by the lowering of the relationship ADP/O, i.e. reliable effect deenergization mentioned mitochondria in the ADP/O-test according to the above description.

In this test system is uniquely identified by the presence of the Regulator received the extract of rat liver - tested faction in obtaining the following results in an integral whole: the decrease in ADP/O in experiment No. 1, no decrease in ADP/O in experiment No. 2 and the decrease in ADP/O in experiment No. 3.

Next contains the Regulator extract liofilizirovanny. Then obtained from freeze-dried concentrated extract was again subjected to testing as described above, including three experiments on the content of the Controller, and used for therapeutic effects on the body of the animal (see Example 2 therapeutic effect).

Example of getting "subcellular fractions".

Procedure C the fight, treatment of liver and chopping implemented, as in the Example of a cellular extract. Chopped liver homogenized in a Potter homogenizer. By the method of differential centrifugation of the homogenate was besieged by the total fraction of nuclei, mitochondria, lysosome and peroxisome. The obtained supernatant was tested on the content of the Regulator as described above (see example of a "cell extract"). Then the supernatant was subjected to ultracentrifugation for complete precipitation remaining in him organelles. The supernatant after ultracentrifugation, not containing cellular organelles ("subcellular fraction")was again tested on the content of the Regulator (see the example of a "cell extract"). Then subcellular fraction was subjected to thermal fractionation by heating at 100°C, denatured protein was separated by centrifugation. Received thermostable subcellular fraction was again tested on the content of the Regulator (see the example of a "cell extract") and were dialyzed. After dialysis the outer volume of concentrated, tested on the content of the Regulator (see the example of a "cell extract"). The obtained concentrate containing the Controller, was used to obtain a therapeutic effect (see Example No. 3 therapeutic impact the ia).

Example obtain the "partially purified" of the Controller.

To obtain the "partially purified" Regulator of rat liver. The initial stage of selection "partially purified" Regulator of rat liver was to obtain a concentrated sub-cellular fractions, which were isolated using procedures as described in Example obtain subcellular fractions from rat liver. The peculiarity consisted in the fact that instead of dialysis used the method of ultrafiltration. The obtained concentrated thermostable fraction of rabbit liver containing the Regulator, which was established by testing (see the example of a "cell extract"), was subjected to fractionation by gel filtration (column chromatography, low pressure). Resulting from this procedure eluate tested on the content of the Regulator (see the example of a "cell extract"). Took the eluate containing the Regulator ("partially purified" Regulator), which is then used to obtain a therapeutic effect (see Example No. 1 therapeutic action).

Similarly, received "partially purified" Regulator of kidney rabbit and rat lung.

An example of receiving cleared Controller.

It was taken 20 rabbits breed "Chinchilla". To obtain a "purified" of the Regulator from rabbit liver was performed procedure p is imename when selecting "partially purified" Regulator of rat liver, described above. The resulting gel-filtration concentrated fraction was subjected to further fractionation using liquid column chromatography, high pressure (HPLC). Resulting from this procedure eluate tested on the content of the Regulator (see the example of a "cell extract"). Took the eluate containing the Controller, which then was subjected to purification using the method of preparative disc electrophoresis. Received after the disk-electrophoresis fraction ("cleaned" the Regulator) was used to obtain a therapeutic effect (see Examples No. 7, 9-12 therapeutic actions and examples No. 8A-8b use of SUPPLEMENTS containing Regulator).

Behavior-based Controller in the above-mentioned preparative procedures (stages of the selection Controller) concluded about the existence of his total negative charge in alkaline medium, its weak hydrophobicity, water solubility and the range of molecular weight from 500 to 15000 Da.

Should be noted that the above characteristics of the Regulator are common for Regulators isolated from any tissue of the vertebrate animals of any species. Their molecular weight also falls in the range from 500 to 15000 Da.

Was measured pogloshena the purified thermostable Regulator of liver in the ultraviolet region of the spectrum. When conducting measurements in aqueous solution, it was found that in the range from 220 nm to 290 nm can be observed from one to two absorption peaks. The number of peaks and the position of their maxima depend on the pH of the solution, which are described measurements.

It should be noted that in all investigated cases there is a consistent trend in the effect of the Regulator on oxidative phosphorylation vysokomineralizovannyh mitochondria of homologous tissue, namely lowering their relationship ADP/O. However, the magnitude of the fall in this ratio may be different from measurement to measurement, which is determined by the conditions of ongoing experience. Therefore, when aggregated empirically obtained values lower ADP/O mitochondria oxidizing succinate, from 2.0 to 1.8 in the control valid values deenergizing effect will be values below 1.8, but often repeated values are not more than 1.7, until the complete uncoupling of oxidative phosphorylation. We obtained the specific values of the ratios of ADP/O achieved with the use of a Regulator of the liver (average is 0.5 to 0.2).

In the present invention for the first time proposed the use of Funds on the basis of the Regulator selected from the liver for the treatment of diseases of other organs of man and animals (and the Way to treat this Medium spans the PTO).

Specific examples of the application of products containing the Regulator from the liver, for pathogenetic therapy of diseases of organs or physiological systems that are functionally dependent on the liver, by tissue-specific regulation of mitochondrial processes in human liver below. The examples are not exclusive and there are other implementation Tools and its therapeutic actions for achieving a technical result.

A. Therapeutic therapeutic effect on patients with astheno-depressive state.

A.1. therapeutic effect of allopathic Remedies on patients with astheno-depressive state.

Example No. 1.

Patient U., 50 years. Diagnosis astheno-depressivee state is set 4 years ago. Complains of depressed mood, unexplained irritability, fatigue when working with documents, which progresses over the last year. Notes an increased need for sweet foods, which was typical for her and in the period before the onset of the disease, but has increased in recent years. Blood sugar within normal limits (if study). Laboratory and instrumental examination of liver pathology has not revealed. Received symptomatic therapy mild antidepressants, which gave unstable improvement.

Means in the form of high-purity Regulator of liver (5 mg/tab) the patient received 1 tablet (resorption in the mouth until dissolved) twice a day. 2 months before the start of the reception Means all other pharmacological agents have been cancelled. After 1 week after beginning treatment was a pathological need for sweet foods. By the end of the first month of treatment the patient said stabilizing emotional status and recovery. Positive results are sustainable within 6 months of symptoms was not renewed.

A.2. therapeutic effect of homeopathic Remedies on patients with astheno-depressive state.

Example No. 2.

Patient K. 67 years. Within 11 months of complaining about a lack of interest in life, unwillingness to communicate with people, lack of health, pathological sleepiness (can sleep several days in a row with breaks of 2-3 h). Notes an increased craving for sweets and sugar, which coincided with the beginning of the disease.

Neurological examination with the use of instrumental methods of diagnosis did not reveal any violations. Confirmed diagnosis of hypertension moderate. The functioning of other organs and physiological systems within normal limits. Blood biochemical parameters, including the level of the sugar, functional tests of the liver, and liver transaminases within normal limits. Diagnosis: astheno-depressive state. Within 7 months (with breaks) had received treatment with antidepressants. Treatment clear positive results has not given.

Homeopathic Remedy (D6), prepared on the basis of high-purity Regulator of the liver, the patient received 5 grains (resorption in the mouth until dissolved) twice a day. Two weeks before the assignment Means all other drugs were removed. From 5th to 9th day after the start of treatment Means disappeared completely subjective symptoms - lethargy, lack of interest in the environment, restored normal operation. Craving for sweet foods and sugar is completely gone after 2 weeks after starting the drug. Starting from the 10th day of the reception Means have any tingling sensation in the epigastrium. In this regard, the receiving Means has been reduced to 3 grains in one meal. Through two days of discomfort, the patient has passed. Despite a full recovery, course Tools (3 pellets twice a day) was continued until the end of the 1st month. Observations over the next 7 months showed that the achieved therapeutic effect is persistent, as described above signs of the disease is not checked.

Example No. 3.

Patient N. 52, Complaints is: lack of interest and others, sleep is shallow, but is marked daytime sleepiness. Increased need for flour and sugary foods. Functional tests of the liver and liver transaminases within normal limits. Diagnosis: astheno-depressive state. In the course of one year (with breaks) had received treatment with antidepressants. Sustainable results treatment to no avail. Homeopathic Remedy (D1), prepared on the basis of high-purity Regulator of the liver, the patient received 3 grains (resorption in the mouth until dissolved) twice a day. Reception Means were carried out in the absence of antidepressants. Subjective symptoms - drowsiness and lack of interest in the environment began to take place in the second week after the beginning of treatment. In the same period, the observed decrease in the need for carbohydrate food. The disappearance of signs of astheno-depressive syndrome was observed in the fourth week of admission.

Example No. 4.

Sick Ya 45 years. Within two years complains of fatigue, tearfulness, irritability and depression, especially in the morning and in the first half of the day. Increased demand for sweet foods.

The surveyed experts. Diagnosis astheno-depressive syndrome to 14 months. ago. Conducted two courses of treatment of mild antidepressants, which gave erratic results. W is Roy the course was completed three months before the treatment. In the last two months of symptoms (depression, tearfulness, irritability) was resumed.

Homeopathic Remedy (D1000), prepared on the basis of high-purity Regulator of the liver, the patient received 2-3 grains (resorption in the mouth until dissolved) 1 time a day for 30 days. By the end of the second week of admission indicated the disappearance of high slezlivo and depressed when you save irritability and fatigue. 3-4 week increased efficiency and decreased irritability. Achieved normalization condition was maintained for 6 months.

Example No. 5.

Patient C. 55 years. In the last three years, complains of low efficiency, lack of interest in communicating with people, increased irritability, and especially after alcohol even in moderation. Changed habits - lost the desire to spend time outdoors, skiing. Gained weight 5 kg for two years. Explains this increased consumption of confectionery. A year ago examined by a specialist. Established diagnosis of astheno-depressive syndrome. Conducted 1 treatment mild antidepressants, which proved ineffective. From continuing antidepressant treatment refused. By the time the treatment of all si is Tomy appear in full.

The patient received homeopathic Remedy (30C), prepared on the basis of high-purity Regulator of the liver. Daily dose: 1-2 grains 1 time per day (resorption in the mouth until dissolved), within 30 days. Reduced symptoms began to celebrate two weeks after the start of the reception Means. The normalization condition happened to the 25-th day of receiving Funds. Within 3 months after receiving Means being satisfactory.

A.3. Therapeutic effect Means in the form of dietary SUPPLEMENTS in patients with astheno-depressive state.

Example No. 6.

Sick Hours, 57 years. For many years, notes the attacks of hunger in the night (about 3 hours). Forced to stand up and take carbohydrate food (sugar, sweets and bread). Along with sleep disorders notes increased tearfulness, fatigue, which is especially pronounced in spring and late autumn. The surveyed experts. Diagnosed astheno-depressive syndrome. Laboratory and instrumental examination of liver pathology has not revealed. Received symptomatic therapy mild antidepressants, which gave an improvement for a short time.

Means in the form of dietary SUPPLEMENTS, prepared on the basis of high-purity Regulator of the liver, the patient received 1 tablet containing 10 µg Regulator (resorption in the mouth until completely dissolved the I) two times a day. For the three months prior to the appointment of Funds in the form of SUPPLEMENTS all other drugs were removed. 2 weeks after you start taking Money nocturnal attacks of hunger disappear. By the end of the first month of use of Funds notes the restoration and stabilization of emotional status. Achieved in the 1-month treatment outcomes are sustainable within 8 months of symptoms was not renewed.

Example No. 7.

Patient S, 60 years. Over the past 2-3 years complains of change in nature, which is reflected in depressed mood, lack of positive emotional reactions and increased slezlivo. In spring and autumn periods, these manifestations are complemented by fatigue and muscle weakness. Sleep shallow, anxious. Constantly carry candy that eats during the day between meals. A specialist was asked a year ago. Diagnosis: astheno-depressive state. Symptomatic therapy soft antidepressant gives temporary (1-2 months) improvement.

Means in the form of dietary SUPPLEMENTS, prepared on the basis of partially purified Regulator of liver (1000 mcg/tab), the patient received 1 tablet (resorption in the mouth until dissolved) once a day. During treatment another treatment was not conducted. Through the week the Liu after receiving Means disappeared increased need for sweet (stopped eating sweets between meals), improved sleep. By the end of the second week noted normalization of mood and increase efficiency, on the 4th week was watery. The normalization condition was maintained for 6 months after stopping treatment.

B. Therapeutic therapeutic effect on patients with chronic obstructive pulmonary disease (COPD).

B.1. therapeutic effect of allopathic Remedies on patients with chronic obstructive pulmonary disease (COPD).

Example No. 8.

Patient N., 55. Suffer from chronic obstructive pulmonary disease (COPD) in the last 7 years. The diagnosis is confirmed radiographically and external respiration function (FER). Complains of shortness of breath when walking, coughing with sputum and lack of appetite. Often suffer from respiratory diseases. Notes fatigue during physical work.

Objectively: the power is reduced, the chest is increased in the anterior-posterior size of the "barrel". Pale skin, weak acrocyanosis. Light: percutere tympanic sound on both sides, can be heard wheezing on both sides. Heart: tone deaf. HELL 130/95, pulse 90.

Means in the form of high-purity Regulator of liver 1 tablet (5 mg/tab.) the patient was taken sublingually twice a day half an hour after eating. 10 days after you start taking Bo the other celebrates the restoration of normal appetite and improve the color of skin. 1 month after you start taking increased efficiency, patient weight increased by 1.0 kg After 2 months after starting the drug, the total weight gain was 2.0 kg Shortness of breath when walking decreased.

B.2. therapeutic effect of homeopathic Remedies on patients with chronic obstructive pulmonary disease (COPD).

Example No. 9.

Patient K., 59 years old. The diagnosis of chronic obstructive pulmonary disease" (COPD) confirmed radiographically and external respiration function (FER). Complains of shortness of breath on exertion and cough emitting Muco-purulent sputum after Smoking and in the morning, as well as the lack of appetite and fatigue. Objectively: pale skin with a yellowish tinge. Light: on both sides percussion with boxed shade. Heart borders are moderately dilated, tone deaf, HELL 144/95, pulse 88. Biochemical parameters of the liver in normal albumin-globulin index moderately reduced. General analysis of blood: ESR - 35 mm/h, hemoglobin - 144 g/l, leucocytes - 8,8×109/HP

The patient is assigned homeopathic Remedy (D1) on the basis of the Regulator of liver 5-6 grains twice a day half an hour after eating, sublingual. By the end of the first month of admission, the patient noted improvement of appetite and normalizing the color of skin, and in addition to the CE 0.5 kg 2 months after you start taking the marked increase in efficiency and reduction of cough, shortness of breath persists. The weight of the patient increased by 1.0 kg, compared with the beginning of the treatment. ESR - 28 mm/h, WBC - 6,3×109/l, hemoglobin - 143 g/L. Albumin-globulin index is unchanged.

Example No. 10.

Patient 3., 52. The diagnosis of chronic obstructive pulmonary disease" (COPD) has been confirmed spirometries and radiographically four years ago. For six years complains of shortness of breath with little exertion and walking fast, cough emitting Muco-purulent sputum after Smoking and in the morning, loss of appetite, fatigue and loss of muscle mass. Objectively: the skin is pale, yellowish. Light: on both sides percussion with boxed shade. Heart borders are moderately dilated, tone deaf, HELL 125/90, pulse 95. Biochemical parameters of the liver in normal albumin-globulin index moderately reduced. General analysis of blood: erythrocyte sedimentation rate of 30 mm/h, hemoglobin - 135 g/l; leucocytes - 7,8×109/HP

The patient is assigned homeopathic Remedy (D1000) on the basis of the Regulator of liver 3 pellets twice a day sublingually. On the third week after the start of treatment the patient was recovering normal appetite and normalizing color dermal tissue is x covers. 2 months after you start taking the marked increase in efficiency and reduction of cough and shortness of breath when walking. The weight of the patient increased by 1.5 kg compared with the beginning of the treatment. ESR - 22 mm/h, WBC - 5,9×109/l, hemoglobin - 143 g/L. Albumin-globulin index is unchanged.

Example No. 11.

Patient S., aged 65. Has a confirmed diagnosis: chronic obstructive pulmonary disease (COPD). Complains of shortness of breath when performing physical work and cough with excessive discharge of Muco-purulent sputum, and lack of appetite and fatigue.

Objectively: pale skin with a yellowish tinge. The patient has exhausted appearance, especially in the upper body. Light: on both sides percussion with boxed shade. Heart - percussion moderately expanded borders, colours deaf, BP 140/90, pulse 84. Liver ultrasound changes were not revealed. Biochemical parameters of the liver in normal albumin-globulin index moderately reduced.

General analysis of blood: ESR - 34 mm/h, hemoglobin - 164 g/l; leukocytes 9,4×109/HP

The patient had used homeopathic Remedy (30C) 5-6 grains twice a day half an hour after eating, sublingual. In the first month of admission, the patient noted improvement of appetite and normalizing the color of skin, as well as Ribalta weight 1 kg 2 months after you start taking the weight of the patient is increased by 2 kg, compared with the beginning of the treatment. The patient also notes the increasing efficiency and reducing coughing while maintaining shortness of breath. ESR 25 mm/h, hemoglobin - 133 g/l, leucocytes - 6,2×109/l Albumin-globulin index is unchanged.

B.3. Therapeutic effect Means in the form of dietary SUPPLEMENTS in patients with chronic obstructive pulmonary disease (COPD).

Example No. 12.

Patient, 48 years of age. Suffer from chronic obstructive pulmonary disease (COPD) in the last 8 years. The diagnosis is confirmed radiographically and method spirometry. Complains of shortness of breath when walking and cough with copious purulent sputum, especially in the morning and after Smoking. Notes lack of appetite, low efficiency and significant weight loss over the past 3 years.

Objectively: the power is lowered (underweight about 10%), chest increased in the anterior-posterior size of the "barrel". Pale skin, easy acrocyanosis. Light: percutane-sound box on both sides, auscultation heard wheezing on both sides, more in the lower lateral parts. Heart: tone deaf. ECG signs of overload of the right ventricle and changes in the myocardium of the left ventricle. HELL 115/70, pulse 92. Liver: ultrasound of the liver - the liver in erenna increased, focal changes are not marked. Biochemical studies of blood disorders of the liver did not reveal. Total protein moderately reduced (5.8 g/l), dysproteinemia.

General analysis of blood: ESR - 42 mm/h, hemoglobin - 148 g/l; leukocytes 9,2×109/HP

The patient applied the Tool in the form of a dietary Supplement, 1 tablet (20 μg partially purified Regulator) sublingually twice a day half an hour after eating. 2 weeks after you start taking patient notes restore normal appetite and color of the skin, and weight gain. 1 month after you start taking the weight of the patient increased by 1.5 kg of Fatigue decreased. Shortness of breath when walking is saved. 2 months after starting the drug, the total weight gain was 2.5 kg Notes the decrease in shortness of breath when walking. Ultrasound normalization of liver size. Total protein (6.2 g/l). Dysproteinemia saved. ESR 28 mm/hour, a Hemoglobin - 142 g/l, leucocytes - 7,4×109/HP

Example No. 13.

Patient, 48 years of age. Suffer from chronic obstructive pulmonary disease (COPD) in the last 8 years. The diagnosis is confirmed radiographically and external respiration function (FER). Complains of shortness of breath when walking and cough with copious purulent sputum, especially in the morning and after Smoking. Notes lack of appetite, low efficiency and a significant loss of wasasa the last 3 years.

Objectively: the power is lowered (underweight about 10%), chest increased in the anterior-posterior size of the "barrel". Pale skin, easy acrocyanosis. Light: percutere tympanic sound on both sides, auscultation heard wheezing on both sides, more in the lower lateral parts. Heart: tone deaf. ECG signs of overload of the right ventricle and changes in the myocardium of the left ventricle. HELL 115/70, pulse 92. Liver: ultrasound of the liver - the liver is moderately increased, focal changes are not marked. Biochemical studies of blood disorders of the liver did not reveal. Total protein moderately reduced (5.8 g/l), dysproteinemia. General analysis of blood: ESR - 42 mm/h, hemoglobin - 148 g/l; leucocytes - 9,2×109/HP

Means in the form of a dietary Supplement, 1 tablet (1000 mg/tab.) on the basis of the Regulator from the liver of the patient administered sublingually twice a day half an hour after eating. 2 weeks after you start taking patient notes restore normal appetite and color of the skin, and weight gain. 1 month after starting the Tool, the weight of the patient increased by 1.5 kg of Fatigue decreased. Shortness of breath when walking is saved. 2 months after starting the drug, the total weight gain was 2.5 kg Notes the decrease in shortness of breath when walking. On ultrasound, normalizati the size of the liver. Total protein (6.2 g/l). The dysproteinemia decreased. ESR - 28 mm/hour, a Hemoglobin - 142 g/l, leucocytes - 7,4×109/HP

C. Therapeutic therapeutic effect on patients with chronic ulcerative colitis of the colon.

B.1. therapeutic effect of allopathic Remedies on patients with chronic ulcerative colitis of the colon.

Example No. 14.

Patient P., 38 years. Suffer from chronic ulcerative colitis colon within 4 years. The diagnosis is verified by two or three years ago in the hospital. Complaints: unstable stool, pain during bowel, escalating in the human diet, tenesmus, and lack of appetite and sleep disturbance. During exacerbation occurs also flatulence, Kale appears mucus and streaks of blood.

Objectively: the patient lowered food, the skin of the face pale, the tongue coated whitish bloom.

The patient used the Tool in the form of high-purity Regulator of liver (5 mg/tab) twice a day between meals. After the first week of admission increased appetite and improved color of the skin. One month later the chair became more regular, mucus appears periodically, decreased abdominal pain, stopped tenesmus, increased duration of sleep.

B.2. therapeutic effect of homeopathic Remedies on patients with chronic ulcerative colitis of the colon.

An example is the 15.

Patient P., 46 years old. The last 10 years, suffering from ulcerative colitis of the colon and vascular dystonia. Repeatedly treated in hospital. Notes that the antibiotic therapy gives unstable remission. Complains of loss of appetite, intermittent abdominal pain, bloating, rumbling, unstable stool - constipation, alternating with diarrhea. Notes the presence of mucus in the feces. In addition, complains of poor sleep and reduced efficiency. Objectively: the patient ascension, skin pale, with an earthy undertone. Heart, lungs within normal limits. The liver is not enlarged, edge palpation soft, painless. Test, liver function test within normal limits. Complete blood count: hemoglobin 122 g/l, leukocytes 7,2×109/l, ESR - 32 mm/h

The patient had used homeopathic Remedy (D12) 5-6 grains twice a day. A week after the beginning of treatment the patient has noted the emergence of appetite, decrease in pain, flatulence and rumbling in the abdomen. Two weeks later recovered from a dream and efficiency. One month after beginning treatment, the patient noted improvement of the chair. Objectively restored normal complexion. Complete blood count: hemoglobin 128 g/l, leukocytes 7,0×109/l, ESR - 26 mm/h

Example No. 16.

Patient S., aged 57. Suffer from chronic ulcers is essential colitis of the colon for more than three years. Complaining on an unstable chair. Occasionally notes the presence of mucus and blood in the stool. Complains well as abdominal pain, poor appetite, shallow sleep, reduced working capacity.

Objectively: the skin is pale, with an earthy undertone. The liver is not enlarged, edge palpation soft, painless. Palpation of the abdomen is marked rumbling along the intestine. Test, liver function test within normal limits. Complete blood count: hemoglobin 122 g/l, leukocytes 7,0×109/l, ESR - 32 mm/h

Almost continuously observes diet. Repeatedly held antibacterial therapy, which did not lead to sustainable positive results.

The patient had used homeopathic Remedy (D1) on the basis of the Regulator of liver 5-6 grains twice a day in between meals in the morning. On the second week after the beginning of reception Means appetite, decreased frequency of pain attacks, as well as bloating and rumbling in the abdomen. The color of the skin has improved. On the 3rd and 4th weeks of sleep became deeper. Notes increase efficiency. After a month of use the improved chair. Complete blood count: hemoglobin 128 g/l, leukocytes 6,5×109/l, ESR - 16 mm/h

Example No. 17.

Patient R., 34 years. Suffer from chronic ulcerative colitis of the colon is for 2 years. Complaints: unstable stool, loss of appetite, irritability, sleeping without sleeping no more than 5-6 hours per day. Exacerbation of the disease relates to improper diet. Experiencing abdominal pain and flatulence, in Calais appears mucus and blood.

Objectively: the patient estensione, skin, face pale, have an earthy hue, the power is reduced.

For biochemical analysis of blood revealed Hypo - and dysproteinemia. Complete blood count: hemoglobin 116 g/l, leukocytes 8,2×109/l, ESR - 34 mm/h

The patient had used homeopathic Remedy (D1000), prepared on the basis of the Regulator from the liver, 2-3 pellets twice a day in between meals. After the first week of receiving Funds increased appetite and improved color of the skin on the face. On the third or fourth week, the patient said more than a regular chair, when you save it mucus, pain in the abdomen, flatulence. The duration of sleep without sleeping pills increased to 7-8 hours, was unprovoked irritability.

Complete blood count: hemoglobin 128 g/l, leukocytes 7,3×109/l, ESR - 18 mm/h Total protein 6.2 g/l, dysproteinemia is stored.

Example 18.

Patient Century, 60 years. Suffer from chronic ulcerative colitis of the colon for more than five years. Complaints: unstable chair, unpleasant owoseni is in the gut, tenesmus, weight loss body. Almost continuously observes the presence of mucus in the feces, and sometimes the presence of blood. Appetite poor, the efficiency is lowered. Complies with diet. Antibiotic therapy was carried out repeatedly, but sustainable positive results were not achieved.

Objectively: the skin with an earthy shade of pale. Palpation of the abdomen is marked rumbling along the intestine.

The patient used a homeopathic Remedy (30C) on the basis of the Regulator of liver 1-2 grains once a day in between meals in the first half of the day due to the ongoing diet. A week after you start taking appetite, improved color of the skin, and stopped unpleasant sensations in the gut and tenesmus. In the third week marks the increasing efficiency and improving sleep. For the month gained weight 1 kg

B.3. Example No. 19. Therapeutic effect Means in the form of dietary SUPPLEMENTS in patients with chronic ulcerative colitis of the colon.

Sick Hours, 41. Suffer from chronic ulcerative colitis colon within 6 years. Complaints: constipation, fatigue, lack of appetite, sleep disturbance. Sometimes abdominal pain, and flatulence. Occasionally notes the presence of mucus and blood in the stool.

Objectively: the patient ACTE is sirawan, the skin of the face is pale, have an earthy hue. Heart, lungs within normal limits. The liver is not enlarged, edge palpation soft, painless. Test, liver function test within normal limits.

Complete blood count: hemoglobin 126 g/l, leukocytes 6,9×109/l, erythrocyte sedimentation rate of 30 mm/h

The patient applied the Tool in the form of a dietary Supplement, 1 tablet (100 μg partially purified Regulator) twice a day. 10 days after the beginning of treatment the patient has noted the emergence of appetite, decrease in pain, flatulence and rumbling in the abdomen. After three weeks, appetite, sleep and health recovered, complexion returned to normal. 2 months after the beginning of treatment the patient notes over a regular chair. Mucus in the stool is stored.

Complete blood count: hemoglobin 124 g/l, leukocytes 7,8×109/l, ESR - 24 mm/h

Example No. 20.

Patient X-VA, age 46. Suffer from chronic ulcerative colitis colon within 5 years. Complains of irregular bowel movements - constipation alternating with diarrhea for several days, when Kale is celebrated mucus streaked with blood, chronic fatigue, shallow sleep, recurrent pain in the lower abdomen. In the last three years on a diet.

Objectively: the patient's condition is unsatisfactory, pale skin, have an earthy hue, tongue coated CE is th bloom. The liver is not enlarged, palpation of the abdomen marked tenderness along the intestine.

The patient applied the Tool in the form of a dietary Supplement, 1 tablet (10 μg partially purified Regulator) twice a day on the background diet. 20 days after receiving the patient noted the emergence of appetite and improve the complexion. After 30 days decreased discomfort in the stomach after a meal. The chair became more regular and decorated. Notes increase efficiency and deeper sleep.

Example No. 21.

Patient K. 58 years. Suffer from chronic ulcerative colitis of the colon for more than 10 years. Repeatedly treated inpatient and outpatient. Complaints: unstable stool with admixture of mucus in the stool, sometimes, in violation of the diet - there were streaks of blood, tenesmus, discomfort during bowel movements. Lack of appetite and health. Sticking to the diet.

Objective: the mood is reduced, ascension. Pale skin, tissue turgor is reduced. Palpation of the abdomen: the liver is normal, it is noted soreness and rumbling in the course of bowels. The heart and lungs without pathology.

The patient used the Tool as a dietary Supplement, 1 tablet (1000 μg partially purified Regulator) twice a day on the background diet in between meals in the morning. Three weeks after the beginning of reception appetite, improved color the t of the skin. After 4 weeks decreased the discomfort in the gut and tenesmus. The chair became more stable, without pathological impurities. For the month gained weight 1 kg

Based on the above examples can be made the following conclusions:

1. The results obtained indicate the achievement of a technical result, namely about effective therapeutic action Means prepared on the basis of the Regulator from the liver of an animal on extrahepatic human disease.

2. Examples 1-7 show that the Tool allows you to get a long-term remission in the treatment of astheno-depressive syndrome.

3. Examples 8-13 indicate that the Tool consistently improves the condition of patients with COPD, as evidenced by the increase in lean body mass.

4. Examples 14-21 indicate that the Tool helps to improve the condition of patients with chronic ulcerative colitis of the colon.

5. Examples 1, 8, 14 indicate that allopathic treatment effectively.

6. Examples 2-5, 9-11, 15-18 indicate that homeopathic Remedy effectively.

7. Examples 6, 7, 12, 13, 19-21 indicate that the Agent is effective in the form of dietary SUPPLEMENTS.

8. These findings indicate the effectiveness of the Tool in the treatment of extrahepatic disease, even in those cases where p is the objective indicators of the condition of the liver can be characterized as normal. Side effects and complications when used in patients not selected.

9. Objective indicators of the condition of patients and the dynamics of the disease allow us to conclude that therapeutic effect Means for COPD patients and patients with chronic ulcerative colitis of the colon due to its protective effect in the liver.

Examples of methods and means of treatment are not the only possible. It should be noted that technical result can be achieved in a wide range of homeopathic dilutions of the Regulator and in a wide range of doses of the dietary Supplement.

It's also doubtless that Means on the basis of the Regulator from the liver can be used for the treatment of diseases of organs and physiological systems that are functionally dependent on the liver, not only in humans but also in animals.

Industrial applicability

The proposed Method pathogenetic therapy of extrahepatic disease, and the proposed Remedy from the liver (options) can be used to treat diseases and/or physiological systems that are dependent on the liver, regardless of the cause of a specific disease. The tool can be used for effective treatment of asthenic-depressive States, as well as to improve the efficiency of the complex is the first therapy for refractory or incurable diseases of other organs, accompanied by chronic intoxication.

1. The way pathogenetic therapy of diseases and/or physiological systems that are functionally dependent liver through tissue-specific regulation of mitochondrial processes in the liver, characterized by the fact that injected into the body in an effective dose of a preparation containing a substance selected from the liver, which slabovidimym, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 to 15000 Yes, when this substance is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen.

2. The method according to claim 1, characterized in that the substance is present in the composition of the extracts or subcellular fractions.

3. The way pathogenetic therapy of diseases and/or physiological systems that are functionally dependent liver through tissue-specific regulation of mitochondrial processes in the liver, characterized by the fact that injected into the body in an effective dose of the agent, prepared according to homeopathic technology, contains a substance selected from pécs is no, which slabovidimym, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 to 15000 Yes, when this substance is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen.

4. The method according to claim 3, characterized in that the substance has a dilution in the range from D1 to D1000 and from 30C to S.

5. The method according to any of PP 4, characterized in that in the treatment of diseases of the Central nervous system, such astenodepressivnyh syndrome, take a homeopathic remedy containing a substance selected from the liver, not less than one week.

6. The method according to any of PP 4, characterized in that in the treatment of chronic obstructive pulmonary disease take homeopathic remedy containing a substance selected from the liver, not less than two months.

7. The method according to any of PP 4, characterized in that in the treatment of chronic ulcerative colitis colon take homeopathic remedy containing a substance selected from the liver, not less than one month.

8. The way pathogenetic therapy of diseases and/or physiological systems, functionally hung the most from the liver, through tissue-specific regulation of mitochondrial processes in the liver, characterizing those that are introduced into the organism in effective doses of the agent in the form of dietary supplements that contain a substance selected from the liver, which slabovidimym, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 to 15000 Yes, when this substance is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen.

9. The method according to claim 8, characterized in that the biologically active additive is a substance in an effective dose of 1-1000 μg and media.

10. The method according to any of PP-9, characterized in that in the treatment of diseases of the Central nervous system, such astenodepressivnyh syndrome, take a dietary Supplement containing a substance selected from the liver, not less than one week.

11. The method according to any of PP-9, characterized in that in the treatment of chronic obstructive pulmonary disease taking dietary Supplement containing a substance selected from the liver, not less than two months.

12. The method according to any of PP-9, ex is different, however, in the treatment of chronic ulcerative colitis colon taking dietary Supplement containing a substance selected from the liver, not less than two months.

13. The means of pathogenetic therapy of diseases and/or physiological systems that are functionally dependent on the liver, tissue-specific regulatory mitochondrial processes in the liver, representing a substance selected from the liver, which slabovidimym, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 to 15000 Yes, when this substance is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen.

14. The means indicated in paragraph 13, characterized in that the substance is present in the composition of the extract or the composition of subcellular fractions.

15. The means of pathogenetic therapy of diseases and/or physiological systems that are functionally dependent on the liver, tissue-specific regulatory mitochondrial processes in the liver, representing the product prepared according to homeopathic technology, contains a substance selected from the liver, which Slaveykov the service, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 to 15000 Yes, when this substance is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen.

16. The means of pathogenetic treatment of diseases and/or physiological systems that are functionally dependent on the liver, tissue-specific regulatory mitochondrial processes in the liver, which represents the biologically active Supplement containing a substance selected from the liver, which slabovidimym, water-soluble, negatively charged at alkaline pH, with a molecular mass of from 500 to 15000 Yes, when this substance is characterized by tissue-specific ability to energysouth vysokomineralizovannye mitochondria from liver, namely to reduce their ratio of phosphorylated to the diphosphate expended during oxidative phosphorylation quantity of atomic oxygen.



 

Same patents:

FIELD: organic chemistry, medicine, hepatology.

SUBSTANCE: invention proposes using 2-amino-4-acetylthiazolo[5,4-b]indole as a substance protecting liver against poisoning with carbon tetrachloride. Invention provides enhancing degree of liver protection against poisoning with carbon tetrachloride.

EFFECT: valuable medicinal property of compound.

1 tbl

FIELD: organic chemistry, medicine, hepatology.

SUBSTANCE: invention proposes using 2-amino-7-bromo-4-acetylthiazolo[5,4-b]indole hydrobromide of the formula (I) as a substance protecting liver against poisoning with carbon tetrachloride and/or possessing prophylactic effect in lung toxic edema. Invention provides enhancing degree of liver protection against poisoning with carbon tetrachloride, decreasing expression of lung edema by the pulmonary coefficient and enhancing viability of animals (with respect to control).

EFFECT: valuable medicinal property of substance.

2 tbl

FIELD: medicine, therapy of internal diseases.

SUBSTANCE: one should introduce lactulose and additionally carry out cryoapheresis at the quantity of about 5-7 procedures at interval of 1-2 d. The innovation provides efficient therapy due to improving hepatic function and activating cerebral metabolic processes.

EFFECT: higher efficiency of therapy.

2 ex

Therapeutic cream // 2307646

FIELD: pharmaceutical industry, in particular production of therapeutic creams for preventing and treatment of dermatological diseases.

SUBSTANCE: claimed cream for psoriasis prophylaxis and treatment contains kilwort, bur beggar-ticks, and medical petrolatum; additionally it contains horse sorrel root, egg albumen, flower bee honey, and lecithin. All component are used in specific component ratio. Cream of present invention make it possible not only to effect on plaque eruption foci, but prevent of new eruption foci formation.

EFFECT: new effective cream for psoriasis prophylaxis and treatment.

2 ex

FIELD: medicine.

SUBSTANCE: method involves per os administering Hepatosan at a dose of 0.8 g/day. The total treatment course is 2 months long.

EFFECT: high activity of 7-α hydroxylase; no adverse side effects observed.

3 tbl

FIELD: medicine.

SUBSTANCE: claimed adsorbent contains spherical activated carbon having size diameter of 0.01-1 mm, specific surface determined in accordance to Langmuir equation of 1000 m2/g or more, ratio of diffraction intensities R of 1.4 or more (R is determined as R = (I15-I35)/(I24-I35) (1), wherein I15 is diffraction intensity at diffraction angle (2θ) of X-ray diffraction is 15°C; I35 is diffraction intensity at diffraction angle (2θ) of X-ray diffraction is 35°C; I24 is diffraction intensity at diffraction angle (2θ) of X-ray diffraction is 24°C), and pore volume having diameter of 7.5-15000 nm is less than 0.25 mg/ml. In another embodiment claimed adsorbent contains abovementioned spherical activated carbon with modified surface. Also disclosed are pharmaceutical composition and method for prevention or treatment of kidney or liver diseases containing said adsorbent.

EFFECT: new adsorbent for peroral administration.

20 cl, 5 ex, 2 tbl, 12 dwg

FIELD: gastroenterology.

SUBSTANCE: method involves simultaneously introducing Panavir and Ganavir. Panavir is introduced intravenously in daily dose 5 ml of 0.004% solution, course: 3 injections with interval 48 h and then, 3 days latter, 2 injections with interval 48 h. Galavin is introduced intramuscularly in daily dose 100 mg, course: 5 injections with interval 24 h and then 10 injections with interval 48 h.

EFFECT: achieved elimination of virus, normalization of clinical and biochemical characteristics in absence of side effects.

FIELD: organic chemistry, pharmaceuticals.

SUBSTANCE: Described are derivatives of general formula I (all symbols are as described in specification), pharmaceutically acceptable salts thereof or cyclodextrin clathrates. Such compounds hardly bind of EP2 subtype of PGE receptor and are useful in prophylaxis of immune diseases, allergy, death of neuronal cells, liver or kidney insufficiency, etc.

EFFECT: new agent for prophylaxis of various diseases.

18 cl, 388 ex, 68 tbl, 3 dwg

FIELD: medicine, gastroenterology.

SUBSTANCE: additionally to general scheme of basic therapy it is necessary to apply FISHant-C preparation once weekly at the quantity of 200.0 g 60 min after light breakfast. Course duration corresponds to about 2-6 mo. Therapy should be carried out once annually. The innovation provides normalization of clinico-biochemical parameters without applying anti-viral therapy.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: medicine, hepatology, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a method for preparing a capsulated formulation of the phospholipid preparation "Fosfogliv" used in treatment and prophylaxis of hepatic diseases. The preparation comprises vegetable phospholipids, glycyrrhizic acid or its salts and accessory substances. Method for preparing the preparation involves mixing phospholipids, glycyrrhizic acid or its salts and accessory substances in alcoholic solution followed by granulation and capsulation of the mixture prepared.

EFFECT: improved preparing method, valuable medicinal properties of preparation.

1 ex

FIELD: medicine.

SUBSTANCE: method involves per os administering Hepatosan at a dose of 0.8 g/day. The total treatment course is 2 months long.

EFFECT: high activity of 7-α hydroxylase; no adverse side effects observed.

3 tbl

FIELD: medicine, clinical pharmacology, restoring therapy.

SUBSTANCE: the suggested preparation is being a lipid fraction isolated out of a king crab's liver Paralithodes comtschatica that contains 10% polyunsaturated fatty acids, 10% alkyl-diacyl glycerides and the complex of natural bioantioxidants being of highly correcting, hypocoagulative and antioxidant properties. The preparation suggested enables to widen the quantity of food BAA of natural origin of lipid-correcting action at pronounced hypocoagulative and antioxidant properties based upon application of natural lipid complex. It could be applied as an efficient means of prophylaxis of cardio-vascular diseases and other pathologies, when lipid exchange is broken and which is accompanied with disorders of hemocoagulation and intensification of lipoperoxidation process.

EFFECT: higher efficiency.

1 ex, 4 tbl

FIELD: biologically active substances, medicine.

SUBSTANCE: claimed agent for parantheral administration represents peptide complex containing 70-90 % of low molecular fraction comprising peptide components with molecular mass 70-184 Da, and peptide concentration of 2.5-2.9 mg/ml. Said agent is obtained from liver of calf not older than 12 months or hog by extraction with acetic acid in presence of zinc chloride. Calf or hog liver are frozen at not less -40°C, conditioned at -20-22°C for at least two months, and ground. Then 3 % acetic acid solution in volume ratio of 1:5 is added at 20±5°C. Extraction is carried out under continuous stirring to produce homogenous slurry. Then 1 % zinc chloride solution is added into slurry in volume ratio of 50:1; mixture is cooled under continuous stirring to 7-16°C; stirred during 1 h after each 4 h defecation for 48 hours. Extract is separated from ballast substances; acetone is added to extract in volume ratio of 1:5, followed by conditioning at 3-5°C for 4 hours. Obtained homogenized deposition is deposited again with acetone two time or more. Further active substance containing precipitate is washed on gravity filter with two-fold volumes of acetone cooled to 7-16°C to produce light-gray precipitate. Precipitate is passed through metal sieve, dried, dissolved in distilled water at room temperature and continuous stirring to produce polypeptide concentration of 2.5-2.9 mg/ml. Solution is centrifuged, filtered, subjected to ultrafiltration purification under back pressure of 1.0 kgf/cm2 or less trough materials with retentiveness of 15000 Da. Glycocol is added into ultrafiltrate up to finish concentration of 10-20 mg/mg at pH 5.6-6.6. Solution is subjected to sterilizing filtration under pressure of 2.0 kgf/cm2 or less, poured in 2 ml ampoules, and autoclaved for 8 min, at 120°C and atmospheric pressure of 1.1 kgf/cm2.

EFFECT: method of increased yield, non-toxic and apirogenic agent of improved purity.

2 cl, 5 ex, 4 tbl, 1 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to the development of a medicament used in carrying out the supporting therapy in metabolism disturbance caused by increased blood cholesterol and made as a tablet. Agent is proposed as two tablets taken in different times. "Litokhol" enhances bile solubility effectively, inhibits formation of cholesterol crystals and stones. Also, it doesn't inhibit cholesterol biosynthesis in hepatocytes and its excesses are removed from body being without its slagging and doing reasons for development of systemic complications.

EFFECT: valuable medicinal property of agent.

7 cl

FIELD: medicine, peptides.

SUBSTANCE: invention relates to a method for preparing a peptide complex from animal raw possessing the tissue-specific activity. Method for preparing an agent for maintaining therapy possessing tissue-specific activity involves milling calf or pig organs of age 12 months, not above, addition of 3% acetic acid solution at temperature 20 ± 5°C and extraction is carried out at constant stirring. Then, in 30 min zinc chloride 1% solution is added, mixture is cooled to temperature 7-16°C at constant stirring followed by stirring for every 1 h in each 4 h and settling for 48 h. Extract is separated from inert substances by separation and acetone is added to extract in the volume ratio = 1:5, mixture is kept at 3-5°C for 4 h and formed precipitate is washed out with out with two-fold volume of acetone cooled to temperature 7-16°C, formed precipitate is rubbed through a metallic sieve and prepared end product is dried at temperature 18 ± 2°C. The end product represents a peptide complex with the content of low-molecular peptide fraction from 70% to 90% and with molecular mass of its peptide components in the range 1000-12000 Da wherein this complex comprises amino acids, mineral substances, trace elements and vitamins in biologically bound form. The complex elicits the expressed tissue-specific activity based on the proposed sequence of technological procedures and conditions for their realization involving temperature, temporal and other indices, and by using substances including the parent raw, a definite extractant and others. Peptide component in the prepared complex has no denaturating properties and retains its regulatory properties that suggests its using as an agent for carrying out the maintaining therapy. The proposed agent can be used in medicinal practice as an agent used in carrying out the maintaining therapy.

EFFECT: improved preparing method, valuable medicinal properties of agent.

9 cl, 42 tbl, 14 ex

FIELD: medicine, biochemistry.

SUBSTANCE: claimed method includes administration of uricase solution into at least one separation column at pH approximately 9-10,5 and reduction from the said column of one or more fractions containing isolated tetra-dimensional urecase aggregate-free uricase, wherein tetra-dimensional urecase aggregates are larger than tetra-dimensional urecase.

EFFECT: 9 cl, 12 ex, 13 dwg.

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with freezing the tissues of animal parenchymatous organs followed by defrosting, homogenization and hydrolysis. Hydrolysis should be conducted at the presence of succinic acid at pH being -4.0 and 45°C. Hydrolyzate should be decanted followed by addition of 3%-caustic soda solution up to pH=7.0; moreover, it is necessary to add novocain powder to hydrolyzate up to 0.4-0.5% concentration and gel of aluminium oxide hydrate at 2-3 mg/ml. The preparation obtained should be packed into 50-ml vials to be sterilized due to autoclaving at the mode of 1.0 atm. for 20 min. The innovation provides less reactogenic final product of prolonged action and increased anti-infectious activity.

EFFECT: higher efficiency.

2 ex, 2 tbl

FIELD: medicine, hepatology, chemical-pharmaceutical industry, biotechnology.

SUBSTANCE: invention relates to a biotransplant used in treatment of chronic hepatitis and liver cirrhosis and comprising mesenchymal stem cells obtained from fetal or donor material. The parent tissue is subjected for disaggregation followed by culturing as fixed colonies in the growth medium containing fetal calve serum and glutamine and passage at low density value with change of medium composition and cultivation is carried out without accumulation cells with mature stroma in culture. Also, invention relates to a method for treatment of chronic hepatitis and liver cirrhosis that involves administration of indicated biotransplants by using venous catheter or by puncture in the portal system veins, or by using arterial catheter in splenic artery, or by puncture in spleen parenchyma, or by intraperitoneal route, or by puncture in gastrocolic omentum. Invention provides enhancing effectiveness in complex effect on damaged liver.

EFFECT: improved preparing method, improved treatment method.

13 cl

FIELD: medicine.

SUBSTANCE: device has Dacron sack usable as envelope introducible into soft tissues of the head. The envelope has two 0.5 mm thick liver tissue leaflets between which hypothalamus tissue leaflets taken from young animal brain and black substance or isolated suprarenal gland medullary substance cells or that of human glands or the like cells taken from human embryo. The Dacron envelope is 25-30 cm long, 5 mm wide and 2 mm thick.

EFFECT: enhanced effectiveness of treatment.

2 cl, 1 dwg

FIELD: agriculture, veterinary science.

SUBSTANCE: the present innovation deals with normalizing the flow of coupling, mating and lambing, the rate of growth for preventing and treating acute and chronic diseases of etiology in animals. One should prepare a tissue preparation due to applying cow's ovaries without yellow bodies, thyroid and parathyroid glands, thymus, pancreas and liver of cattle up to 4-yr-aged terms. The organs mentioned should be separately kept for 9-10 d in a fridge to be separately reduced thrice with a meat chopper, diluted with fresh running water at 1:2 ratio, extracted for 4 h in glassware at room temperature, thoroughly mixed every 10-15 min, treated in water bath for 1 h at 58-59 C, separately filtered through double-layered sterile gauze to keep a filtrate 4 times at 1-d-long interval in water bath at 58-59 C for 1 h. Components should be mixed so, that their ratio in preparation should be, weight%: ovarian tissue emulsion 10.3, thyroid and parathyroid emulsion 10.3, that of thymus 10.3, that of pancreas 17.2, that of liver 20.6, ACD f-2 10.3, formalin 0.4, natural bee honey 20.6. Before injection the preparation should be mixed and introduced per 1/2 dosage into dorsal lumbar muscles at 0.02-0.04 ml/kg animal body weight. The innovation provides complex biostimulation, activation of hormonal regulation of animal body.

EFFECT: higher efficiency of prophylaxis and therapy.

1 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing bio-organic preparation into patient organism. The preparation is introduced at a daily dose of 2 ml intramuscularly during 3-4 weeks.

EFFECT: enhanced effectiveness of treatment.

2 dwg

Up!